Vitamin D and systemic cancer: is this relevant to malignant melanoma?

  title={Vitamin D and systemic cancer: is this relevant to malignant melanoma?},
  author={Joy E. Osborne and Peter E. Hutchinson},
  journal={British Journal of Dermatology},
Summary 1,25‐dihydroxyvitamin D3[1,25(OH)2D3] is a well‐known potent regulator of cell growth and differentiation and there is recent evidence of an effect on cell death, tumour invasion and angiogenesis, which makes it a candidate agent for cancer regulation. The classical synthetic pathway of 1,25(OH)2D3 involves 25‐ and 1α‐hydroxylation of vitamin D3, in the liver and kidney, respectively, of absorbed or skin‐synthesized vitamin D3. There is recent focus on the importance in growth control… 

Selective vitamin D receptor modulators and their effects on colorectal tumor growth

Vitamin D and Sphingolipids: Role in Bone and Neural System

The biological actions of 1,25(OH)2D3 and SLs, in particular S1P, share many common effectors, including calcium regulation, growth factor expression, inflammatory cytokines, etc., but whether they could act synergistically is still unknown and deserves further investigation.

Vitamin D and cancer.

Correcting vitamin D deficiency may decrease the risk of developing colon cancer, while the novel Gemini 1,25(OH)2D3-analogs have the potential for therapeutic application in human colon cancer.

1,25‐Dihydroxyvitamin D3 enhances NK susceptibility of human melanoma cells via Hsp60‐mediated FAS expression

The data suggest that 1α,25(OH)2D3 acts as an anticancer agent by increasing expression of Fas on the surface of melanoma cells through Hsp60 induction and strengthens caspase sensitivity to Fas‐mediated apoptotic pathway by NK cells.

Vitamin D, Cancer Risk, and Mortality.

Potential Use of 1-25-dihydroxyvitamin D in the Diagnosis and Treatment of Papillary Thyroid Cancer

  • Ting ZhangH. Zhang Ping Zhang
  • Medicine, Biology
    Medical science monitor : international medical journal of experimental and clinical research
  • 2018
1,25(OH)2D3 may be a new, potential biomarker for the identification of PTC and NG and may also become a potential target for drug action to treat PTC through CAMP.

Vitamin D and Cancer

The aim of this review is to highlight the relationship between vitamin D and cancer, summarizing several mechanisms proposed to explain the potential protective effect of vitamin D against the development and progression of cancer.

Vitamin D Receptor Polymorphisms and Cancer.

There is some indication that VDR polymorphisms may modulate the risk of some cancer sites and in future studies VDR genetic variation should be integrated also with assessment of vitamin D status and stratified by ethnicity.

Expression of 25-Hydroxyvitamin D-1 α-Hydroxylase ( 1 αOHase , CYP 27 B 1 ) Splice Variants in HaCaT Keratinocytes and Other Skin Cells : Modulation by Culture Conditions and UV-B Treatment In Vitro

The keratinocyte represents the only cell type where the complete enzymatic machinery for the synthesis of 1,25(OH)2D from 7-DHC is present and where the synthesis from 7DHC has been shown, and the pattern of CYP27B1 splice variants varied depending on the cell density, the calcium concentration of the medium, and UV-B treatment.

The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms

The evidence in favour of a role for 1,25‐ (OH)2D3 in protection against the progression of melanocytic lesions is discussed and the mechanisms by which 1, 25‐(OH) 2D3 may act to protect against melanoma development and progression are summarized.



Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites.

1,25-(OH)2D3 had a biphasic effect on the replication of two distinct human cancer cell lines, i.e., the breast cancer T-47D and the malignant melanoma MM96, an effect analogous to that of estrogens on the Breast cancer cell line MCF-7.

Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis.

The results strongly suggest that anti-angiogenic compounds with relatively low toxicity and their combinations could be beneficial in the treatment of some angiogenesis-associated malignancies.

Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity.

1α,25-Dihydroxyvitamin D3[ 1,25-(OH)2D3] inhibits the proliferation of many cancer cells in culture, but not the aggressive human prostate cancer cell line DU 145. We postulated that the

A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis.

The present findings indicate that a colon-specific potent carcinogen interferes with the biological expression of 1,25(OH)2D3 and that vitamin D administered prior to a carcinogenic insult is able to reduce significantly the incidence of colon tumors, presumably acting as an antiproliferative or differentiation-promoting agent.

Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.

It is demonstrated that liarozole augments the ability of 1,25-(OH)2D3 to inhibit DU 145 cell growth, and the mechanism appears to be due to inhibition of 24-hydroxylase activity, leading to increased1,25-dihydroxyvitamin D3 half-life and augmentation of homologous up-regulation of VDR.

1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells.

  • G. SchwartzM. H. WangM. ZangR. SinghG. Siegal
  • Biology, Medicine
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 1997
The hypothesis that 1,25 D reduces the risk of invasive prostate cancer and suggest a role for vitamin D compounds in the chemoprevention ofvasive prostate cancer is supported.

1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition.

The results suggest that the level of vitamin D receptor correlates with the degree of differentiation in human colon cancer cell lines and may serve as a useful biological marker in predicting clinical outcome in patients.

Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation.

In PC3 cells stably expressing VDR [PC3(VDR)] at levels comparable to LNCaP, 1,25 D treatment resulted in only moderate growth inhibition, which further support the contention that VDR expression, althou...

1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells.

  • K. KoliJ. Keski‐Oja
  • Biology, Chemistry
    Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research
  • 2000
Vitamin D and its derivatives were able to decrease the secretion of urokinase PA and tissue-type PA activity in a dose-dependent manner and to increase PA inhibitor 1 secretion, leading to reduced total PA activity.